文献速递间质性肺疾病

吡非尼酮治疗非IPF进行性纤维化间质性肺疾病(RELIEF):双盲随机安慰剂对照2b期试验

Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.
PubMed 文献 · Lancet Respir Med · 2021-03-30

RELIEF是一项在德国17个中心开展的多中心双盲随机安慰剂对照2b期试验,纳入127例非IPF的进行性纤维化ILDs患者,随机接受吡非尼酮或安慰剂治疗48周。

要点

  • 吡非尼酮可能减缓非IPF进行性纤维化ILDs患者的FVC下降
  • 研究提前终止,结果需谨慎解读
  • 吡非尼酮组死亡1例(非呼吸性),安慰剂组死亡5例(3例呼吸性)

核心结论

  • 在常规治疗仍恶化的非IPF纤维化ILDs患者中,加用吡非尼酮可能减缓以FVC下降衡量的疾病进展。
  • 鉴于研究提前终止,结果应谨慎解读。

研究设计与样本

  • 多中心、双盲、随机、安慰剂对照、平行2b期试验(RELIEF),在德国17个间质性肺疾病中心开展。
  • 纳入18-80岁、四种非IPF进行性纤维化ILD诊断的患者,随机1:1接受口服吡非尼酮或匹配安慰剂治疗48周。
  • 共随机分配127例患者:吡非尼酮组64例,安慰剂组63例。
  • 主要终点为意向治疗人群从基线至第48周FVC%预计值的绝对变化。

主要发现

  • 吡非尼酮组死亡1例(非呼吸性,2%),安慰剂组死亡5例(其中3例呼吸性,8%)。
  • 两组最常见严重不良事件为感染和侵染(吡非尼酮组5例[8%],安慰剂组10例[16%])、包括疾病恶化在内的一般疾病(2例[3%] vs 7例[11%])及心脏疾病(1例[2%] vs 5例[8%])。

关键数值与推荐

  • 纳入标准包括FVC 40-90%预计值、DLCO 10-90%预计值、常规治疗下FVC年下降至少5%预计值(基于入组前6-24个月内至少三次测量)。
  • 排除既往接受过任何抗纤维化治疗的患者。
  • 吡非尼酮剂量:第1周267 mg每日三次,第2周534 mg每日三次,此后801 mg每日三次。

临床怎么用

  • 对于常规治疗仍恶化的非IPF进行性纤维化ILDs患者,加用吡非尼酮可能减缓FVC下降,但需结合提前终止的背景谨慎评估。
  • 治疗期间需关注感染、疾病恶化及心脏相关严重不良事件。

局限性

  • 研究因招募缓慢基于无效性中期分析提前终止,可能影响结果的把握度与解释。
  • 样本量较小(共127例),且仅纳入四种特定诊断的非IPF纤维化ILDs患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pirfenidone has been shown to slow disease progression in patients with idiopathic pulmonary fibrosis (IPF). However, there are few treatment options for progressive fibrotic interstitial lung diseases (ILDs)) other than IPF. In view of the pathomechanistic and clinical similarities between IPF and other progressive fibrotic ILDs, we aimed to assess the efficacy and safety of pirfenidone in patients with four non-IPF progressive fibrotic ILDs. METHODS: We did a multicentre, double-blind, randomised, placebo-controlled, parallel phase 2b trial (RELIEF) in 17 centres with expertise in ILD in Germany. Eligible participants were patients aged 18-80 years with progressive fibrotic ILD due to four diagnoses: collagen or vascular diseases (ie, connective tissue disease-associated ILDs), fibrotic non-specific interstitial pneumonia, chronic hypersensitivity pneumonitis, or asbestos-induced lung fibrosis. Other eligibility criteria included a forced vital capacity (FVC) of 40-90% predicted, a diffusing capacity of the lung for carbon monoxide of 10-90% predicted, and an annual decline of FVC of at least 5% predicted despite conventional therapy, based on at least three measurements within 6-24 months before enrolment. Patients who had received any previous antifibrotic therapy were excluded. We randomly assigned patients (1:1) to either oral pirfenidone (267 mg three times per day in week 1, 534 mg three times per day in week 2, and 801 mg three times per day thereafter) or matched placebo, added to their ongoing medication. Randomisation was done centrally using permuted block randomisation with varying block sizes stratified by the four diagnostic groups. Patients, investigators, statisticians, monitors, and the study coordinator were masked to treatment assignment until database closure. The placebo-controlled study period was 48 weeks (including up-titration). The primary endpoint was absolute change in percentage of predicted FVC (FVC % predicted) from baseline to week 48 in the intention-to-treat population, with imputation of missing data by the smallest sum of squared differences and attribution of deceased patients to the lowest rank in a rank ANCOVA model. Additionally, we did linear mixed-model repeated measures slope analyses of FVC % predicted longitudinal data over the course of the study as a prespecified sensitivity analysis and post-hoc sensitivity analyses of the primary endpoint in the intention-to-treat population using imputation methods of last observation carried forward [LOCF] and a regression-based multiple imputation procedure. Safety was assessed in all patients who received at least one dose of study medication. This trial is registered with EudraCT 2014-000861-32; DRKS00009822 and is no longer recruiting. FINDINGS: Between April 5, 2016, and Oct 4, 2018, we randomly assigned 127 patients to treatment: 64 to pirfenidone, 63 to placebo. After 127 patients had been randomised, the study was prematurely terminated on the basis of an interim analysis for futility triggered by slow recruitment. After 48 weeks and in the overall population of 127 patients, rank ANCOVA with diagnostic group included as a factor showed a significantly lower decline in FVC % predicted in the pirfenidone group compared with placebo (p=0·043); the result was similar when the model was stratified by diagnostic group (p=0·042). A significant treatment effect was also observed when applying the LOCF and multiple imputation methods to analyses of the primary endpoint. The median difference (Hodges-Lehmann estimate) between pirfenidone and placebo groups for the primary endpoint was 1·69 FVC % predicted (95% CI -0·65 to 4·03). In the linear mixed-model repeated measures slope analysis of FVC % predicted, the estimated difference between treatment and placebo groups from baseline to week 48 was 3·53 FVC % predicted (95% CI 0·21 to 6·86) with imputation of deaths as prespecified, or 2·79 FVC % predicted (95% CI 0·03 to 5·54) without imputation. One death (non-respiratory) occurred in the pirfenidone group (2%) and five deaths (three of which were respiratory) occurred in the placebo group (8%). The most frequent serious adverse events in both groups were infections and infestations (five [8%] in the pirfenidone group, ten [16%] in the placebo group); general disorders including disease worsening (two [3%] in the pirfenidone group, seven [11%] in the placebo group); and cardiac disorders (one ([2%] in the pirfenidone group, 5 [8%] in the placebo group). Adverse events (grade 3-4) of nausea (two patients on pirfenidone, two on placebo), dyspnoea (one patient on pirfenidone, one on placebo), and diarrhoea (one patient on pirfenidone) were also observed. INTERPRETATION: In view of the premature study termination, results should be interpreted with care. Nevertheless, our data suggest that in patients with fibrotic ILDs other than IPF who deteriorate despite conventional therapy, adding pirfenidone to existing treatment might attenuate disease progression as measured by decline in FVC. FUNDING: German Center for Lung Research, Roche Pharma.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Behr J, Prasse A, Kreuter M, et al. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021. PMID: 33798455. doi:10.1016/S2213-2600(20)30554-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。